Risedronian sodu jest bisfosfonianem hamującym resorpcję kości.
Risedronian sodu jest bisfosfonianowym inhibitorem resorpcji kości. Ma powinowactwo do kryształów hydroksyapatytu w kości i działa jako środek antyresorpcyjny oraz jest inhibitorem syntazy difosforanu farnezylu (FPP), co skutkuje hamowaniem aktywności osteoklastów i zmniejszeniem resorpcji i obrotu kostnego. Risedronian sodu jest stosowany w leczeniu osteoporozy pomenopauzalnej i choroby Pageta.
Ta strona może zawierać tekst przetłumaczony maszynowo.
European journal of cancer (Oxford, England : 1990), 49(15), 3176-3183 (2013-07-16)
Prostate cancer truly is an age-associated disease. Due to the increased life expectancy and more sensitive diagnostic techniques in the Western world, prostate cancer is diagnosed more frequently and with rapidly increasing incidence and prevalence rates. However, age above 65
Scandinavian journal of rheumatology, 42(5), 408-416 (2013-03-27)
To investigate whether treatment with a bisphosphonate would influence the subchondral bone plate stiffness and the development of cartilage damage in Dunkin Hartley guinea pigs, which develop osteoarthritis (OA) spontaneously. Fifty-six 3-month-old male Dunkin Hartley guinea pigs were randomized into
Journal of bone and mineral metabolism, 31(5), 562-570 (2013-04-12)
Low persistence with osteoporosis medication is associated with higher fracture risk. Previous studies estimated that 1-year persistence with osteoporosis medication is low. Our aim was to study persistence with osteoporosis medication among patients with long-term follow-up (to 5 years). The InterAction
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(8), 2345-2352 (2013-04-25)
This observational study showed that after 2 years, both risedronate and alendronate lowered the risk of hip and nonvertebral fractures compared with patients filling in a single bisphosphonate prescription. Post hoc analyses of the placebo-controlled trials suggested earlier effects for
The role of bisphosphonates (BP) in early breast cancer (BC) has been considered controversial. We performed a meta-analysis of all randomized controlled trials (RCTs) that appraised the effects of BP on survival in early BC. RCTs were identified by searching
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
